Latest Regulatory Engagement News

Jameson Resources has marked significant progress in advancing its Crown Mountain steelmaking coal project, doubling its pre-tax NPV to US$942 million and moving closer to final environmental approvals and development permits expected by the end of 2026.

SkyCity Entertainment Group posted a solid half-year profit increase to NZD 12.1 million despite a slight revenue dip, bolstered by a major equity raise and a clean bill on its Adelaide casino licence.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Alicanto Minerals has completed its acquisition of the Mt Henry Gold Project in Western Australia, setting the stage for an ambitious 50,000-metre drilling campaign aimed at expanding the existing 915,000-ounce gold resource.

St Barbara Limited has expanded its Nova Scotia exploration portfolio with 44 new targets near its 15-Mile Processing Hub, aiming to extend the mine life beyond 11 years. The company has acquired 174 exploration licences and plans extensive drilling and sampling in 2026.

Macquarie Group reports solid 3Q26 results with robust profit growth across divisions and a strong capital surplus, underpinned by strategic technology investments and regulatory compliance.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Manuka Resources has secured a US$22.5 million loan facility and completed a A$15 million capital raise, positioning itself for a production restart in late Q2 2026 amid soaring silver and gold prices.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Ardea Resources has made disciplined progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, supported by renewed Major Project Status and full funding from a Japanese consortium. Completion is on track for mid-2026 amid robust resource updates and strategic partnerships.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.